A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)
Research payments
$3,219,921
Through program year 2025, $3,219,921 in research payments was reported against A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063), across 128 payments.
- Paid by (largest first)
- Celgene Corporation; E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $919,176 | 42 |
| 2024 | Research | $1,035,971 | 43 |
| 2023 | Research | $1,256,038 | 40 |
| 2022 | Research | $8,736 | 3 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Stuart Shafer Vero Beach, FL Named on 4 payments
- Faria Amjad Washington, DC Named on 3 payments
- Ariel Antezana Alexandria, LA Named on 3 payments
- Irena Dujmovic Basuroski Chapel Hill, NC Named on 3 payments
- Mark Gudesblatt Islip, NY Named on 3 payments
- David Moore Ames, IA Named on 3 payments
- Aram Zabeti Cincinnati, OH Named on 3 payments
- Natasha Frost Madison, WI Named on 2 payments
- Ahmed Obeidat Milwaukee, WI Named on 2 payments
- Mirela Cerghet Detroit, MI Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.